EP1280530A1 - Treatment of fibromyalgia and chronic fatigue syndrome - Google Patents

Treatment of fibromyalgia and chronic fatigue syndrome

Info

Publication number
EP1280530A1
EP1280530A1 EP01928355A EP01928355A EP1280530A1 EP 1280530 A1 EP1280530 A1 EP 1280530A1 EP 01928355 A EP01928355 A EP 01928355A EP 01928355 A EP01928355 A EP 01928355A EP 1280530 A1 EP1280530 A1 EP 1280530A1
Authority
EP
European Patent Office
Prior art keywords
quinoline
trans
pharmaceutically acceptable
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01928355A
Other languages
German (de)
French (fr)
Inventor
David W. Robertson
Robert B. Mccall
Robert C. Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of EP1280530A1 publication Critical patent/EP1280530A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the treatment of neuromuscular disorders and, more specifically, to the use of apomorphine, bromocriptine, pergolide, ropinirole, octahydropyrazolo[3,4-g]quinolines, and trans-(+)-substituted-5,5a,6,7,8,9-,9a, 10- octahydropyrirnido[4,5-g]quinolines, and their pharmaceutically acceptable salts to treat, or to prepare a medicament for treating, symptoms of fibromyalgia syndrome and chronic fatigue syndrome.
  • Chronic fatigue syndrome also referred to as chronic fatigue immune disorders, chronic fatigue immune disorders syndrome, yuppie flu, fatigue - chronic, and chronic fatigue and immune dysfunction syndrome
  • CFS chronic fatigue syndrome
  • patients with CFS generally report various nonspecific symptoms, including weakness, muscle aches and pains, excessive sleep, malaise, fever, sore throat, tender lymph nodes, impaired memory and/or mental concentration, insomnia, and depression.
  • the exact cause of CFS is unknown and, to date, there are no specific tests to confirm the diagnosis of CFS, though a variety of tests are usually done to exclude other possible causes of the symptoms.
  • Fibromyalgia syndrome also referred to as fibromyalgia, fibromyositis, fibrositis, or myofasical pain syndrome
  • FMS Fibromyalgia syndrome
  • CFS and FMS are commonly used to treat CFS and FMS.
  • examples of the more common medications include hypnotics, immune suppressants, various other prescribed medications, and an array of non-prescription medications.
  • examples of other prescription drugs include opioid antagonists, sodium retention agents/beta blockers, calcium channel blockers/histamine blockers, anti-depressants, allergy medications, and acute anxiety medications.
  • opioid antagonists sodium retention agents/beta blockers
  • calcium channel blockers/histamine blockers include anti-depressants, allergy medications, and acute anxiety medications.
  • side effects ranging from mild side effects, e.g., drowsiness, dizziness, and nausea to serious side effects, e.g., addiction and liver damage.
  • the present invention reveals several compounds that can be used to treat, or to prepare a medicament for treating, these conditions. These compounds include apomorphine, bromocriptine, pergolide, ropinirole, octahydropyrazolo[3,4-g]quinolines, and trans-(+)-substituted-5,5a,6,7,8,9-,9a, 10- octahydropyrimido[4,5-g]quinolines, and their pharmaceutically acceptable salts.
  • U.S. Patent No. 3,717,639 discloses apomorphine and methods of preparation of the same.
  • 5,756,483 discloses intranasal formulations for apomorphine and the use of the same as a therapy for Parkinson disease.
  • U.S. Patent No 5,939,094 discloses transdermal formulations comprising apomorphine.
  • U.S. Patent No. 6,200,983 discloses oral formulations for apomorphine and the use of apomorphine as a therapy for human sexual dysfunction.
  • U.S. Patent No. 3,752,814 discloses bromocriptine and the process of making the same.
  • U.S. Patent No.3,752,888 discloses information on the formulations, dose levels and administration for inhibiting lactation, as well as process of synthesis, for bromocriptine.
  • U.S. Patent No.5, 679,685 discloses information on the formulations, dose levels and administration of bromocriptine for inhibiting lactation.
  • U.S. Patent No. 4,166,182 discloses the preparation of pergolide and its oral or parenteral administration as a prolactin inhibitor and in the treatment of Parkinson's Disease.
  • German patent application DE 4240798 discloses a pharmaceutical composition containing ergot derivatives, including pergolide, for oral, sublingual, parenteral, percutaneous or nasal administration.
  • U.S. Patent No. 6,001,390 discloses a pharmaceutical composition containing ergot derivatives, including pergolide, for transdermal administration.
  • U.S. Patent Nos. 4,452,808 and 5,336,781 disclose ropinirole and methods for preparing ropinirole and its pharmaceutically acceptable salts.
  • U.S. Patent Nos. 4,452,808 and 4,912,126 discloses methods for preparing pharmaceutical compositions for oral, rectal, or parenteral administration of ropinirole as a treatment for cardiovascular disorders or depression.
  • European Patent Application No. 299602A discloses the use of ropinirole as a treatment for Parkinson's disease, as well as pharmaceutical compositions for oral, rectal, parenteral, or transdermal administration of ropinirole.
  • U.S. Patent No. 5,807,570 discloses transdermal formulations and administration of ropinirole.
  • U.S. Patent No. 4,198,415 discloses octahydropyrazolo[3,4-g]quinolines and method for preparing the compounds and pharmaceutical compositions thereof for oral or parenteral administration for treating Parkinsonism and for inhibiting prolactin secretion.
  • U.S. Patent No. 4,528,290 discloses the formulations for oral and parenteral administration for octahydropyrazolo[3,4-g]quinolines.
  • U.S. Patent No. 4,501,890 discloses trans-( ⁇ )-substituted-5,5a,6,7,8,9-,9a,10- octahydropyrimido[4,5-g]quinolines and method for preparing the same, as well formulations for oral or parenteral administration for treating Parkinson's syndrome, sexual dysfunction, depression, hypertension, and elevated prolactin levels.
  • U.S. Patent No. 4,521,421 discloses information on method of preparation and formulations of trans-( ⁇ )- substituted-5,5a,6,7,8,9-,9a,10- octahydropyrimido[4,5-g]quinolines for oral and parenteral administration for treating sexual dysfunction.
  • the invention is directed to the use of certain known compounds to treat, or prepare
  • the present invention provides for the use of several classes of compounds, and their pharmaceutically acceptable salts to treat, or prepare medicaments for treating, symptoms of fibromyalgia (FMS) or chronic fatigue syndrome (CFS).
  • FMS fibromyalgia
  • CFS chronic fatigue syndrome
  • “Pharmaceutically acceptable” as used throughout the entire document refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
  • “treat” or “treating” it is meant to make less hard to bear, reduce or decrease, or lighten or relieve patients of the symptoms of FMS or CFS.
  • a suitable compound in the present invention is apomorphine and a pharmaceutically acceptable salt thereof.
  • Apomorphine, or (R)-5,6,6a,7-Tetrahydro-6- methyl-4H-dibenzo[de,g]quinoline-10,ll-diol or 6a ⁇ -aporphine-10,l l-diol can be structurally represented by formula (I)
  • a pharmaceutical composition comprising apomorphine or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier can be administered.
  • Apomorphine hydrochloride is preferred; however, other pharmacologically acceptable moieties thereof can be utilized as well.
  • other acceptable acid addition salts are the hydrobromide, the hydroiodide, the bisulfate, the phosphate, the acid phosphate, the lactate, the citrate, the tartarate, the salicylate, the succinate, the maleate, the gluconate, and the like.
  • Apomorphine can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, transdermal patch, suspension or solution.
  • a typical formulation for apomorphine comprises 0.25 to 10 milligrams (mg) of the active and as inactive ingredients, microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hydroxypropylmethylcellulose, titanium dioxide, lactose, triacetin, and FD&C Blue #2 aluminum lake.
  • Apomorphine in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, sublingually, buccally, intranasally, transdermally, or parenterally. It is preferred that apomorphine be administered parenterally by subcutaneous injection, intravenous injection or infusion, or by transdermal delivery.
  • the effective dosage of apomorphine is generally from about 0.25 to about 6 mg/dose/person, once or twice per day. The exact dose to be administered and the dose frequency of apomorphine should be easily determined by the attending physician or clinician.
  • bromocriptine is bromocriptine, or a pharmaceutically acceptable salt thereof.
  • Bromocriptine, or (5' ⁇ )-2-Bromo-12 ' -hydroxy-2' - (I-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; 2-bromoergocryptine; or 2- bromo- ⁇ -ergokryptin, can be structurally represented by formula (II) below.
  • Bromocriptine may be obtained by brominating ergocryptine in an inert solvent, with a mild brominating agent, e.g. N-bromophthalimide, and purifying the resulting bromocriptine in manner known per se.
  • Bromocriptine can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, suspension or solution. Solid oral preparations have long been commercially available as bromocriptine mesylate (PARLODEL® marketed by Novartis Pharmaceuticals Corp.) in tablet and capsule form containing 2.5 and 5 mg of bromocriptine, respectively.
  • PARLODEL® bromocriptine mesylate
  • Bromocriptine in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, sublingually, buccally, transdermally, or parenterally. It is preferred that bromocriptine be administered orally.
  • the therapeutic effective amount of bromocriptine in the present invention is generally from about 2.5 to about 15 mg/day/person. Normally, administration of bromocriptine should be initiated at a low daily dosage of about 1.25 mg per day, and on an individual basis, the dosage is increased slowly and gradually until an optimal therapeutic response is achieved. The exact dose to be administered and the dose frequency for bromocriptine should be easily determined by the attending physician or clinician.
  • Another suitable compound in the present invention is pergolide, or a pharmaceutically acceptable salt thereof.
  • Pergolide or (8 ⁇ )-8-[(Methylthio)methyl]-6- propylergoline; D-6- ⁇ -propyl-8 ⁇ -methylmercaptomethylergoline; or LY-141B, can be structurally represented by formula (HI) below.
  • Pergolide can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, suspension or solution.
  • Solid oral pergolide preparations have long been commercially available as pergolide mesylate (PERMAX® by Athena Neurocsiences) in tablet form containing 0.05, 0.25, and 1 mg of pergolide, respectively. These preparations are approved in the United States for use in the treatment of Parkinson's disease.
  • Pergolide in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, sublingually, buccally, transdermally, nasally, or parenterally. It is preferred that pergolide be administered orally and parenterally, and more preferred that pergolide be administered orally.
  • the therapeutic effective amount of pergolide in the present invention is generally from about 0.75 to about 5 mg/day/person. Normally, administration of pergolide should be initiated with a daily dosage of 0.05 mg for the first two days. The dosage should then be gradually increased by 0.1 - 0.25 mg/day every third day until an optimal therapeutic dosage is achieved. Pergolide is usually administered in divided doses 3 times per day. The exact dose to be administered and the dose frequency for pergolide should be easily determined by the attending physician or clinician.
  • Ropinirole or 4-[2-(Dipropylamino)ethyl]-l,3- dihydro-2H-indol-2-one; 4-[2-(di- ⁇ -propylamino)ethyl]-2(3H)-indolone; or 4-(2-di-n- propylaminoethyl)-2-(3 ⁇ )-indolone, can be structurally represented by formula (IN) below.
  • Suitable salts will be apparent to those skilled in the art and include, for example acid addition salts, preferably the hydrochloride.
  • Ropinirole and its pharmaceutically acceptable salts can be prepared by the methods described in U.S. Patent No. 4,452,808. Information on formulations and administration of ropinirole as a treatment for cardiovascular disorders or Parkinson's disease is described in U.S. Patent Nos. 4,912126 and 5,807,570, and EP-299602-A, all incorporated herein by reference.
  • Ropinirole can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, transdermal patch, suspension or solution.
  • Solid oral ropinirole preparations have been commercially available as ropinirole hydrochloride (REQJUJP by SmithKline Beecham) in tablet form containing 0.25, 1 mg, 2 mg, 4 mg, and 5 mg of ropinirole, respectively. These preparations are approved in the United States for use in the treatment of Parkinson's disease.
  • Ropinirole in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, sublingually, transdermally, rectally, or parenterally. It is preferred that ropinirole be administered orally and parenterally, and more preferred that ropinirole be administered orally.
  • the therapeutic effective amount of ropinirole in the present invention is generally from about 0.25 to about 25 mg/day /person. It is typically given 3 times daily. The dosage is normally initiated at a low dosage at about 0.25 mg three times daily, and increased gradually to achieve a maximum therapeutic effect, balanced against the principal side effects of nausea, dizziness, somnolence and dyskinesia. The exact dose to be administered and the dose frequency should be easily determined by the attending physician or clinician.
  • Rl is H, COOH, COO(Cl -C3) alkyl or CH2 X wherein X is C ⁇ , Cl, I, Br, OH, OCH3, SCH3, SO2 CH3, OSO2 -(Cl -C.sub.3)-alkyl, O--SO2 -tolyl, OSO2 -phenyl or CO ⁇ H2.
  • Examples of compounds of formula (Na or Nb) include, but are not limited to, following compounds: trans-( ⁇ )-5-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-lH(and 2H)-pyrazolo[3,4- g]quinoline and dihydrochloride salts thereof; trans-( ⁇ )-5-n-propyl-7-methylmercaptomethyl-4,4a,5,6,7,8,8a,9-octahydro-lH( and 2H)-pyrazolo[3,4-g]quinoline and dihydrochloride salts thereof; trans-( ⁇ )-5-(Cl -C3)alkyl (or allyl)-7-(Cl -C3)alkoxy carbonyl-4,4a,5,6,7,8,8a,9- octahydro- lH(and 2H)-pyrazolo[3,4-g]quinoline; trans-( ⁇ )-5-n-propyl
  • a particularly preferred compound of formulae (Na) and (Vb) can have the formula (Vc)
  • R is Cl -C3 alkyl or allyl
  • Rl is CH2 X wherein X is C ⁇ , CO ⁇ H2, SCH3, SO2 CH3 and OCH3.
  • Another particularly preferred compound of formulae (Va) and (Vb) is a trans-(+) stereoisomer existing as a tautomeric pair of the formula (Ve)
  • R is methyl, ethyl, n-propyl, or allyl.
  • An especially preferred compound of formulae (Va) and (Vb) is quinpirole, or pharmaceutically acceptable salts thereof.
  • Compounds of formulae (la) and (lb) can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, transdermal patch, suspension or solution. Pharmaceutical formulations for these compounds are further described in U.S. Patent Nos. 4,198,415 and 4,528,290, both incorporated herein by reference.
  • a compound of formulae (Va) and (Vb) in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, sublingually, transdermally, or parenterally. It is preferred that the compound be administered orally and parenterally.
  • the therapeutic effective amount of a compound of formulae (Va) and (Vb) in the present invention is generally from about 0.01 to about 15 mg kg/dose by oral administration and from about 0.0025 to about 2.5 mg/kg/dose by parenteral administration.
  • the oral dosage is typically given 3 - 4 times per day, giving a daily dosage range of about 0.3 to about 60 mg/kg per day.
  • the exact dose to be administered and the dose frequency should be easily determined by the attending physician or clinician.
  • Still other suitable compounds in the present invention are trans-(+)-racemates of the formula (VI)
  • NHR3, NR4 R5 and R2 is H, CH3, Cl or Br wherein R3 is methyl, ethyl or n-propyl, Cl - C3 alkyl-CO, phenyl-CO or substituted phenyl-CO wherein said substituents are 1 or 2 members of the group: Cl, F, Br, CH3, C2 H5, CH3 O, C2 H5 O and CF3; R4 and R5 are individually methyl, ethyl or n-propyl and pharmaceutically-acceptable acid addition salts thereof.
  • the two racemates in question are the trans-( ⁇ )-racemate— trans-( ⁇ )-2-amino-6- alkyl or allyl-4-permissibly-substituted-5,5a,6,7,8,9,9a, 10-octahydropyrimido[4,5-g ]quinoline— and the corresponding cis-( ⁇ )-racemate.
  • the trans-(-)-enantiomer (Via) is one of the two stereoisomers represented by (VI) and is preferred for the present invention.
  • Specifically preferred compounds include, for example, trans-(+.)-2-amino-6-n-propyl- 5,5a,6,7,8,9,9a,10-octahydropyrimido[4,5-g ]quinoline, trans-(-)-2-amino-6-n-propyl- 5,5a,6,7, 8,9,9a, 10-octahydropyrimido[4,5-g]quinoline, and trans-(-)-2-amino-6-n-propyl- 5,5a,6,7, 8,9,9a, 10-octahydropyrimido[4,5-g]quinoline dihydrochloride.
  • An especially preferred compound of formula (VI) is quinelorane or pharmaceutically acceptable salts thereof.
  • the compounds of formula (VI) and their pharmaceutically acceptable salts can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, transdermal patch, suspension or solution.
  • Route of administration for these compounds in the known appropriate pharmaceutical dosage form for a given route of administration includes oral, sublingual, transdermal, and parenteral route, with oral being the preferred route.
  • the therapeutic effective amount of the compounds of formula (VI) in the present invention is generally from about 0.1 to about 100 mcg/kg/dose by oral administration and from about 0.25 to about 25 mcg/kg/dose by parenteral administration.
  • the oral dosage is typically given 3 - 4 times per day. The exact dose to be administered and the dose frequency should be easily determined by the attending physician or clinician.
  • formulations for the compounds in the present invention may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques known in the art. Such techniques include the step of bringing into association the active ingredient and pharmaceutical carriers or excipients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • the compounds and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
  • a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
  • a formulation in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a formulation in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • the compounds and their pharmaceutically acceptable salts which are active when administered parenterally can be formulated as solutions or suspensions.
  • a formulation for parenteral administration may contain anti-oxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in freeze-dried (lyophilized) conditions requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the kind previously described.
  • a typical suppository formulation comprises a compound described above or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
  • a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the ingredient to be administered in a suitable liquid carrier.
  • Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising the active ingredient to be administered in a pharmaceutical acceptable carrier.
  • Topical delivery systems include a transdermal patch and a transdermal gel containing the ingredient to be administered.
  • Formulations suitable for nasal administration wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of 20 to 500 microns, which is administered in the manner in which snuff is administered, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Suitable formulations for nasal administration, wherein the carrier is a liquid, as for example, a nasal spray or nasal drops include aqueous or oily solutions of the active ingredient.
  • the exact dosage for a given compound described above for treating symptoms of FMS or CFS of the present invention will depend on factors such as route of administration, the dosage form, the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking, and should be easily determined by a skilled physician with experience in prescribing biologically active drugs designed to modulate central nervous system, movement and related psychological and physiological disorders of the type described here. Patients with milder forms of FMS and CFS would be expected to need less drug, patients with more severe forms of the disease may be expected to need more drug.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to the treatment of neuromuscular disorders and, more specifically, to the use of apomorphine, bromocriptine, pergolide, ropinirole, octahydropyrazolo[3,4-g]quinolines, and trans-(±)-substituted-5,5a,6,7,8,9-,9a,10-octahydropyrimido[4,5g]quinolines, and their pharmaceutically acceptable salts to treat, or to prepare a medicament for treating, symptoms of fibromyalgia syndrome and chronic fatigue syndrome.

Description

TREATMENT OF FTBROMYALGIA AND CHRONIC FATIGUE SYNDROME
FIELD OF THE INVENTION The present invention relates to the treatment of neuromuscular disorders and, more specifically, to the use of apomorphine, bromocriptine, pergolide, ropinirole, octahydropyrazolo[3,4-g]quinolines, and trans-(+)-substituted-5,5a,6,7,8,9-,9a, 10- octahydropyrirnido[4,5-g]quinolines, and their pharmaceutically acceptable salts to treat, or to prepare a medicament for treating, symptoms of fibromyalgia syndrome and chronic fatigue syndrome.
BACKGROUND OF THE INVENTION Chronic fatigue syndrome (CFS), also referred to as chronic fatigue immune disorders, chronic fatigue immune disorders syndrome, yuppie flu, fatigue - chronic, and chronic fatigue and immune dysfunction syndrome, is a clinically defined condition characterized by profound tiredness or fatigue. In addition, patients with CFS generally report various nonspecific symptoms, including weakness, muscle aches and pains, excessive sleep, malaise, fever, sore throat, tender lymph nodes, impaired memory and/or mental concentration, insomnia, and depression. The exact cause of CFS is unknown and, to date, there are no specific tests to confirm the diagnosis of CFS, though a variety of tests are usually done to exclude other possible causes of the symptoms.
Fibromyalgia syndrome (FMS), also referred to as fibromyalgia, fibromyositis, fibrositis, or myofasical pain syndrome, is a rheumatic condition generally characterized by widespread pain in fibrous tissues, muscles, tendons, and other connective tissues, fatigue, headaches, lack of restorative sleep, and numbness. Thus, FMS shares many clinical features with CFS. Similar to CFS, there are no specific diagnostic tests for FMS. Because of the similarity in clinical features between CFS and FMS, CFS and FMS are often treated similarly.
Many medications are commonly used to treat CFS and FMS. Examples of the more common medications include hypnotics, immune suppressants, various other prescribed medications, and an array of non-prescription medications. Examples of other prescription drugs include opioid antagonists, sodium retention agents/beta blockers, calcium channel blockers/histamine blockers, anti-depressants, allergy medications, and acute anxiety medications. However, there are no known medications that permanently resolve the symptoms of either CFS or FMS. In addition, many of the currently used medications produce side effects ranging from mild side effects, e.g., drowsiness, dizziness, and nausea to serious side effects, e.g., addiction and liver damage.
Accordingly, there is clearly a need for better treatments for chronic fatigue syndrome and fibromyalgia. Now, the present invention reveals several compounds that can be used to treat, or to prepare a medicament for treating, these conditions. These compounds include apomorphine, bromocriptine, pergolide, ropinirole, octahydropyrazolo[3,4-g]quinolines, and trans-(+)-substituted-5,5a,6,7,8,9-,9a, 10- octahydropyrimido[4,5-g]quinolines, and their pharmaceutically acceptable salts. U.S. Patent No. 3,717,639 discloses apomorphine and methods of preparation of the same. U.S. Patent No. 5,756,483 discloses intranasal formulations for apomorphine and the use of the same as a therapy for Parkinson disease. U.S. Patent No 5,939,094 discloses transdermal formulations comprising apomorphine. U.S. Patent No. 6,200,983 discloses oral formulations for apomorphine and the use of apomorphine as a therapy for human sexual dysfunction.
U.S. Patent No. 3,752,814 discloses bromocriptine and the process of making the same. U.S. Patent No.3,752,888 discloses information on the formulations, dose levels and administration for inhibiting lactation, as well as process of synthesis, for bromocriptine. U.S. Patent No.5, 679,685 discloses information on the formulations, dose levels and administration of bromocriptine for inhibiting lactation.
U.S. Patent No. 4,166,182 discloses the preparation of pergolide and its oral or parenteral administration as a prolactin inhibitor and in the treatment of Parkinson's Disease. German patent application DE 4240798 discloses a pharmaceutical composition containing ergot derivatives, including pergolide, for oral, sublingual, parenteral, percutaneous or nasal administration. U.S. Patent No. 6,001,390 discloses a pharmaceutical composition containing ergot derivatives, including pergolide, for transdermal administration.
U.S. Patent Nos. 4,452,808 and 5,336,781 disclose ropinirole and methods for preparing ropinirole and its pharmaceutically acceptable salts. U.S. Patent Nos. 4,452,808 and 4,912,126 discloses methods for preparing pharmaceutical compositions for oral, rectal, or parenteral administration of ropinirole as a treatment for cardiovascular disorders or depression. European Patent Application No. 299602A discloses the use of ropinirole as a treatment for Parkinson's disease, as well as pharmaceutical compositions for oral, rectal, parenteral, or transdermal administration of ropinirole. U.S. Patent No. 5,807,570 discloses transdermal formulations and administration of ropinirole.
U.S. Patent No. 4,198,415 discloses octahydropyrazolo[3,4-g]quinolines and method for preparing the compounds and pharmaceutical compositions thereof for oral or parenteral administration for treating Parkinsonism and for inhibiting prolactin secretion. U.S. Patent No. 4,528,290 discloses the formulations for oral and parenteral administration for octahydropyrazolo[3,4-g]quinolines.
U.S. Patent No. 4,501,890 discloses trans-(±)-substituted-5,5a,6,7,8,9-,9a,10- octahydropyrimido[4,5-g]quinolines and method for preparing the same, as well formulations for oral or parenteral administration for treating Parkinson's syndrome, sexual dysfunction, depression, hypertension, and elevated prolactin levels. U.S. Patent No. 4,521,421 discloses information on method of preparation and formulations of trans-(±)- substituted-5,5a,6,7,8,9-,9a,10- octahydropyrimido[4,5-g]quinolines for oral and parenteral administration for treating sexual dysfunction. SUMMARY OF THE INVENTION
The invention is directed to the use of certain known compounds to treat, or prepare
medicaments for treating, symptoms of fibromyalgia syndrome and chronic fatigue
syndrome, two debilitating conditions for which no known effective treatments exist. The
compounds described herein are apomorphine, bromocriptine, pergolide, ropinirole,
octahydropyrazolo[3,4-g]quinolines, and trans-(±)-substituted-5,5a,6,7,8,9-,9a,10-
octahydropyrimido[4,5-g]quinolines, and their pharmaceutically acceptable salts. The
preparation of medicaments, dosages and routes of administration are all provided to the
extent needed to identify and treat patients in need thereof.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides for the use of several classes of compounds, and their pharmaceutically acceptable salts to treat, or prepare medicaments for treating, symptoms of fibromyalgia (FMS) or chronic fatigue syndrome (CFS). "Pharmaceutically acceptable" as used throughout the entire document refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability. By "treat" or "treating" it is meant to make less hard to bear, reduce or decrease, or lighten or relieve patients of the symptoms of FMS or CFS.
A suitable compound in the present invention is apomorphine and a pharmaceutically acceptable salt thereof. Apomorphine, or (R)-5,6,6a,7-Tetrahydro-6- methyl-4H-dibenzo[de,g]quinoline-10,ll-diol or 6aβ-aporphine-10,l l-diol, can be structurally represented by formula (I)
(I) and exists in a free base form or as an acid addition salt. The method of synthesis and preparation of pharmaceutical formulations for apomorphine, as well as its use as a therapy for Parkinson disease or human sexual dysfunction, is known in the art. See, e.g., U.S. Patent Nos. 3,717,639, 5,756,483, 5,939,094, and 6,200,983, all incorporated herein by reference.
For the purposes of the present invention, a pharmaceutical composition comprising apomorphine or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier can be administered. Apomorphine hydrochloride is preferred; however, other pharmacologically acceptable moieties thereof can be utilized as well. In addition to the hydrochloride salt, other acceptable acid addition salts are the hydrobromide, the hydroiodide, the bisulfate, the phosphate, the acid phosphate, the lactate, the citrate, the tartarate, the salicylate, the succinate, the maleate, the gluconate, and the like.
Apomorphine can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, transdermal patch, suspension or solution. A typical formulation for apomorphine comprises 0.25 to 10 milligrams (mg) of the active and as inactive ingredients, microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hydroxypropylmethylcellulose, titanium dioxide, lactose, triacetin, and FD&C Blue #2 aluminum lake.
Apomorphine in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, sublingually, buccally, intranasally, transdermally, or parenterally. It is preferred that apomorphine be administered parenterally by subcutaneous injection, intravenous injection or infusion, or by transdermal delivery. The effective dosage of apomorphine is generally from about 0.25 to about 6 mg/dose/person, once or twice per day. The exact dose to be administered and the dose frequency of apomorphine should be easily determined by the attending physician or clinician.
Another suitable compound in the present invention is bromocriptine, or a pharmaceutically acceptable salt thereof. Bromocriptine, or (5' ά)-2-Bromo-12 ' -hydroxy-2' - (I-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; 2-bromoergocryptine; or 2- bromo-α-ergokryptin, can be structurally represented by formula (II) below.
(π)
The method of synthesis and preparation of pharmaceutical formulations for bromocriptine, as well as its use and administration for inhibiting lactation, is known in the art. See, e.g., U.S. Patent Nos 3,752,814, 3,752,888, and 5,679,685, all incorporated herein by reference.
Bromocriptine may be obtained by brominating ergocryptine in an inert solvent, with a mild brominating agent, e.g. N-bromophthalimide, and purifying the resulting bromocriptine in manner known per se. Bromocriptine can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, suspension or solution. Solid oral preparations have long been commercially available as bromocriptine mesylate (PARLODEL® marketed by Novartis Pharmaceuticals Corp.) in tablet and capsule form containing 2.5 and 5 mg of bromocriptine, respectively. These preparations are approved in the United States for use in the treatment of certain hyperprolactinemia-associated dysfunctions and acromegaly, in the prevention of physiological lactation, and in the treatment of Parkinson's disease and prevention of tolerance to Levodopa therapy for Parkinson's disease. Bromocriptine in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, sublingually, buccally, transdermally, or parenterally. It is preferred that bromocriptine be administered orally.
The therapeutic effective amount of bromocriptine in the present invention is generally from about 2.5 to about 15 mg/day/person. Normally, administration of bromocriptine should be initiated at a low daily dosage of about 1.25 mg per day, and on an individual basis, the dosage is increased slowly and gradually until an optimal therapeutic response is achieved. The exact dose to be administered and the dose frequency for bromocriptine should be easily determined by the attending physician or clinician. Another suitable compound in the present invention is pergolide, or a pharmaceutically acceptable salt thereof. Pergolide, or (8β )-8-[(Methylthio)methyl]-6- propylergoline; D-6-π-propyl-8β-methylmercaptomethylergoline; or LY-141B, can be structurally represented by formula (HI) below.
(HI)
The method of synthesis and preparation of pharmaceutical formulations for pergolide, as well as its use and administration as a therapy for Parkinson's disease or as a prolactin inhibitor, is known in the art. See, e.g., U.S. Patent Nos. 4,166,182 and 6,001,390, and German patent application DE 4240798, all incorporated herein by reference. Pergolide can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, suspension or solution. Solid oral pergolide preparations have long been commercially available as pergolide mesylate (PERMAX® by Athena Neurocsiences) in tablet form containing 0.05, 0.25, and 1 mg of pergolide, respectively. These preparations are approved in the United States for use in the treatment of Parkinson's disease.
Pergolide in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, sublingually, buccally, transdermally, nasally, or parenterally. It is preferred that pergolide be administered orally and parenterally, and more preferred that pergolide be administered orally. The therapeutic effective amount of pergolide in the present invention is generally from about 0.75 to about 5 mg/day/person. Normally, administration of pergolide should be initiated with a daily dosage of 0.05 mg for the first two days. The dosage should then be gradually increased by 0.1 - 0.25 mg/day every third day until an optimal therapeutic dosage is achieved. Pergolide is usually administered in divided doses 3 times per day. The exact dose to be administered and the dose frequency for pergolide should be easily determined by the attending physician or clinician.
Another suitable compound in the present invention is ropinirole or a pharmaceutically acceptable salt thereof. Ropinirole, or 4-[2-(Dipropylamino)ethyl]-l,3- dihydro-2H-indol-2-one; 4-[2-(di-π-propylamino)ethyl]-2(3H)-indolone; or 4-(2-di-n- propylaminoethyl)-2-(3Η)-indolone, can be structurally represented by formula (IN) below.
(IN) Suitable salts will be apparent to those skilled in the art and include, for example acid addition salts, preferably the hydrochloride.
Ropinirole and its pharmaceutically acceptable salts can be prepared by the methods described in U.S. Patent No. 4,452,808. Information on formulations and administration of ropinirole as a treatment for cardiovascular disorders or Parkinson's disease is described in U.S. Patent Nos. 4,912126 and 5,807,570, and EP-299602-A, all incorporated herein by reference.
Ropinirole can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, transdermal patch, suspension or solution. Solid oral ropinirole preparations have been commercially available as ropinirole hydrochloride (REQJUJP by SmithKline Beecham) in tablet form containing 0.25, 1 mg, 2 mg, 4 mg, and 5 mg of ropinirole, respectively. These preparations are approved in the United States for use in the treatment of Parkinson's disease.
Ropinirole in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, sublingually, transdermally, rectally, or parenterally. It is preferred that ropinirole be administered orally and parenterally, and more preferred that ropinirole be administered orally. The therapeutic effective amount of ropinirole in the present invention is generally from about 0.25 to about 25 mg/day /person. It is typically given 3 times daily. The dosage is normally initiated at a low dosage at about 0.25 mg three times daily, and increased gradually to achieve a maximum therapeutic effect, balanced against the principal side effects of nausea, dizziness, somnolence and dyskinesia. The exact dose to be administered and the dose frequency should be easily determined by the attending physician or clinician.
Other suitable compounds in the present invention are those generically or specifically disclosed in U.S. Patent Nos. 4,198,415 and 4,528,290. These compounds are generically referred to as trans-(±)-octahydro pyrazolo[3,4-g]quinolines and can exist as tautomers of formula (Na)
1
(Na) and formula (Nb)
(Nb) or their pharmaceutically acceptable salts, wherein: R is H, CΝ, Cl - C3 alkyl, allyl or benzyl and
Rl is H, COOH, COO(Cl -C3) alkyl or CH2 X wherein X is CΝ, Cl, I, Br, OH, OCH3, SCH3, SO2 CH3, OSO2 -(Cl -C.sub.3)-alkyl, O--SO2 -tolyl, OSO2 -phenyl or COΝH2. Examples of compounds of formula (Na or Nb) include, but are not limited to, following compounds: trans-(±)-5-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-lH(and 2H)-pyrazolo[3,4- g]quinoline and dihydrochloride salts thereof; trans-(±)-5-n-propyl-7-methylmercaptomethyl-4,4a,5,6,7,8,8a,9-octahydro-lH( and 2H)-pyrazolo[3,4-g]quinoline and dihydrochloride salts thereof; trans-(±)-5-(Cl -C3)alkyl (or allyl)-7-(Cl -C3)alkoxy carbonyl-4,4a,5,6,7,8,8a,9- octahydro- lH(and 2H)-pyrazolo[3,4-g]quinoline; trans-(±)-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydro-lH(and 2H)- pyrazolo[3,4-g]quinoline; and trans-(±)-5-methyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydro-lH(and 2H)- pyrazolo [3 ,4-g] quinoline.
A particularly preferred compound of formulae (Na) and (Vb) can have the formula (Vc)
(Vc) and formula (Nd)
(Nd)
or a pharmaceutically acceptable salt thereof , wherein: R is Cl -C3 alkyl or allyl, and
Rl is CH2 X wherein X is CΝ, COΝH2, SCH3, SO2 CH3 and OCH3. Another particularly preferred compound of formulae (Va) and (Vb) is a trans-(+) stereoisomer existing as a tautomeric pair of the formula (Ve)
(Ve)
and formula (Vf)
(Vf)
wherein R is methyl, ethyl, n-propyl, or allyl.
An especially preferred compound of formulae (Va) and (Vb) is quinpirole, or pharmaceutically acceptable salts thereof. Quinpirole, or lH-Pyrazolo[3,4-g]quinoline, 4,4a,5,6,7,8,8a,9-octahydro-5-proρyl-, (4aR,8aR)- (9CI) or lH-Pyrazolo[3,4-g]quinoline, 4,4a,5,6,7,8,8a,9-octahydro-5-propyl-, (4aR-trans)-; (-)-Quinpirole; LY 156258, can be structurally represented by the formula (Vg) below.
(Vg)
Compounds of formulae (Va) and (Vb) can be prepared by any suitable methods.
Methods for preparing these compounds are further described in U.S. Patent Nos. 4,198,415 and 4,528,290, both incorporated herein by reference. Compounds of formulae (la) and (lb) can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, transdermal patch, suspension or solution. Pharmaceutical formulations for these compounds are further described in U.S. Patent Nos. 4,198,415 and 4,528,290, both incorporated herein by reference. A compound of formulae (Va) and (Vb) in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, sublingually, transdermally, or parenterally. It is preferred that the compound be administered orally and parenterally.
The therapeutic effective amount of a compound of formulae (Va) and (Vb) in the present invention is generally from about 0.01 to about 15 mg kg/dose by oral administration and from about 0.0025 to about 2.5 mg/kg/dose by parenteral administration. The oral dosage is typically given 3 - 4 times per day, giving a daily dosage range of about 0.3 to about 60 mg/kg per day. The exact dose to be administered and the dose frequency should be easily determined by the attending physician or clinician. Still other suitable compounds in the present invention are trans-(+)-racemates of the formula (VI)
(VI)
or stereoisomers thereof of formula (Via)
(Via) or pharmaceutically acceptable salts thereof, wherein: R is Cl - C3 alkyl or allyl, Rl is
NH2, NHR3, NR4 R5 and R2 is H, CH3, Cl or Br wherein R3 is methyl, ethyl or n-propyl, Cl - C3 alkyl-CO, phenyl-CO or substituted phenyl-CO wherein said substituents are 1 or 2 members of the group: Cl, F, Br, CH3, C2 H5, CH3 O, C2 H5 O and CF3; R4 and R5 are individually methyl, ethyl or n-propyl and pharmaceutically-acceptable acid addition salts thereof.
Compounds represented by formula (VI) are generically or specifically disclosed in U.S. Patent Nos. 4,521,421 and 4,501,890, and are generically referred to as trans-(±)- substituted-5,5a,6,7,8,9-,9a,10- octahydropyrimido[4,5-g]quinolines. These compounds can exist as two racemates, ordinarily denominated as the trans-(±) racemate and the cis-(±) racemate. The two racemates in question are the trans-(±)-racemate— trans-(±)-2-amino-6- alkyl or allyl-4-permissibly-substituted-5,5a,6,7,8,9,9a, 10-octahydropyrimido[4,5-g ]quinoline— and the corresponding cis-(±)-racemate. The trans-(-)-enantiomer (Via) is one of the two stereoisomers represented by (VI) and is preferred for the present invention. Specifically preferred compounds include, for example, trans-(+.)-2-amino-6-n-propyl- 5,5a,6,7,8,9,9a,10-octahydropyrimido[4,5-g ]quinoline, trans-(-)-2-amino-6-n-propyl- 5,5a,6,7, 8,9,9a, 10-octahydropyrimido[4,5-g]quinoline, and trans-(-)-2-amino-6-n-propyl- 5,5a,6,7, 8,9,9a, 10-octahydropyrimido[4,5-g]quinoline dihydrochloride.
An especially preferred compound of formula (VI) is quinelorane or pharmaceutically acceptable salts thereof. Quinelorane, or pyrido[2,3-g]quinazolin-2-amine, 5,5a,6,7,8,9,9a,10-octahydro-6-propyl-, (5aR,9aR)- (9CI) or pyrido[2,3-g]quinazolin-2- amine, 5,5a,6,7,8,9,9a,10-octahydro-6-propyl-, (5aR-trans)-, can be structurally represented by formula (VIb) below.
(VIb) The compounds of formula (VI) and pharmaceutically acceptable salts thereof can be prepared according to the procedures set forth in U.S. Patent Nos, 4,501,890 and
4,521,421. Information on the pharmaceutical formulations for these compounds, as well as their use and administration for treating Parkinson's syndrome, sexual dysfunction, depression, hypertension, and elevated prolactin levels, is described in U.S. Patent Nos, 4,501,890 and 4,521,421, both incorporated herein by reference. The compounds of formula (VI) and their pharmaceutically acceptable salts can be prepared in any conventional dosage form such as a capsule, tablet, chewable tablet, powder, transdermal patch, suspension or solution. Route of administration for these compounds in the known appropriate pharmaceutical dosage form for a given route of administration includes oral, sublingual, transdermal, and parenteral route, with oral being the preferred route.
The therapeutic effective amount of the compounds of formula (VI) in the present invention is generally from about 0.1 to about 100 mcg/kg/dose by oral administration and from about 0.25 to about 25 mcg/kg/dose by parenteral administration. The oral dosage is typically given 3 - 4 times per day. The exact dose to be administered and the dose frequency should be easily determined by the attending physician or clinician.
The formulations for the compounds in the present invention may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques known in the art. Such techniques include the step of bringing into association the active ingredient and pharmaceutical carriers or excipients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
The compounds and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s), for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
A formulation in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
A formulation in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
The compounds and their pharmaceutically acceptable salts which are active when administered parenterally (i.e. by injection or infusion) can be formulated as solutions or suspensions. A formulation for parenteral administration may contain anti-oxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in freeze-dried (lyophilized) conditions requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the kind previously described.
A typical suppository formulation comprises a compound described above or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
Formulations suitable for topical administration in the mouth include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the ingredient to be administered in a suitable liquid carrier.
Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising the active ingredient to be administered in a pharmaceutical acceptable carrier. Topical delivery systems include a transdermal patch and a transdermal gel containing the ingredient to be administered.
Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of 20 to 500 microns, which is administered in the manner in which snuff is administered, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations for nasal administration, wherein the carrier is a liquid, as for example, a nasal spray or nasal drops, include aqueous or oily solutions of the active ingredient. The exact dosage for a given compound described above for treating symptoms of FMS or CFS of the present invention will depend on factors such as route of administration, the dosage form, the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking, and should be easily determined by a skilled physician with experience in prescribing biologically active drugs designed to modulate central nervous system, movement and related psychological and physiological disorders of the type described here. Patients with milder forms of FMS and CFS would be expected to need less drug, patients with more severe forms of the disease may be expected to need more drug.
It will be apparent to one of ordinary skill in the art that many changes and modifications can be made in the invention without departing from the spirit or scope of the invention.

Claims

1. A method of treating the symptoms of fibromyalgia syndrome and chronic fatigue syndrome, comprising administering to a patient suffering fibromyalgia syndrome or chronic fatigue syndrome an effective amount of a compound selected from the group consisting of apomorphine, bromocriptine, pergolide, ropinirole, one of the octahydropyrazolo[3,4-g]quinolines, and one of the trans-(+)-substituted-5,5a,6,7,8,9- ,9a, 10- octahydropyrimido[4,5-g]quinolines, or a pharmaceutically acceptable salt of any said compound.
2. The method of claim 1 wherein said compound is apomorphine or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 wherein the effective amount of apomorphine or pharmaceutically acceptable salt thereof is from about 0.25 to about 12 mg/day.
4. The method of claim 1 wherein said compound is bromocriptine or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 wherein the effective amount of bromocriptine or a pharmaceutically acceptable salt thereof is from about 2.5 to about 15 mg/day.
6. The method of claim 1 wherein said compound is pergolide or a pharmaceutically acceptable salt thereof.
7. The method of claim 6 wherein the effective amount of pergolide is from about 0.75 to about 5 mg/day.
8. The method of claim 1 wherein said compound is ropinirole or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 wherein the effective amount of ropinirole or a pharmaceutically acceptable salt thereof is from about 0.25 to about 25 mg/day.
10. The method of claim 1 wherein said octahydropyrazolo[3,4-g]quinoline is a trans- (±)stereoisomer existing as a tautomeric pair of the formula
and formula
wherein: R is H, CN, Cl - C3 alkyl, allyl or benzyl and
Rl is H, COOH, COO(Cl -C3) alkyl or CH2 X wherein X is CN, Cl, I, Br, OH, OCH3, SCH3, SO2 CH3, OSO2 -(Cl -C3)-alkyl, O--SO2 -tolyl, OSO2 -phenyl or CONH2, or a pharmaceutically-acceptable salt thereof.
11. The method of claim 10 wherein R is Cl -C3 alkyl or allyl and Rl is H or CH2 X wherein X is CN, CONH2, SCH3, OCH3 or SO2 CH3.
12. The method of claim 10 wherein R is H, CN or benzyl and Rl is H.
13. The method of claim 10 wherein R is Cl -C3 alkyl or allyl and Rl is COO(Cl -C3) alkyl, or CH2 X wherein X is Br, I, Cl, OH, OSO2 -(Cl -C3) alkyl, OSO2 -tolyl or OSO2 - phenyl.
14. The method of claim 10 wherein said octahydropyrazolo[3,4-g]quinoline is trans- (+)-5-n-propyl-4,4a,5,6,7,8,8a,9-octahydro-lH(and 2H)-pyrazolo[3,4-g]quinoline or dihydrochloride salts tereof.
15. The method of claim 10 wherein said octahydropyrazolo[3,4-g]quinoline is trans- (±)-5-n-propyl-7-methylmercaptomethyl-4,4a,5,6,7,8,8a,9-octahydro-lH( and 2H)- pyrazolo[3,4-g]quinolin or dihydrochloride salts thereof.
16. The method of claim 10 wherein said octahydropyrazolo[3,4-g]quinoline is trans- (+)-5-(Cl -C3)alkyl (or allyl)-7-(Cl -C3)alkoxy carbonyl-4,4a,5,6,7,8,8a,9-octahydro- lH(and 2H)-pyrazolo[3,4-g]quinoline.
17. The method of claim 10 wherein said octahydropyrazolo[3,4-g]quinoline is trans- (+)-5-n-propyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydro-lH(and 2H)-pyrazolo[3,4- g]quinoline.
18. The method of claim 10 wherein said octahydropyrazolo[3,4-g]quinoline is trans- (±)-5-methyl-7-ethoxycarbonyl-4,4a,5,6,7,8,8a,9-octahydro-lH(and 2H)-pyrazolo[3,4- g]quinoline.
19. The method of claim 10 wherein said octahydropyrazolo[3,4-g]quinoline is a trans- (±)stereoisomer existing as a tautomeric pair of the formula
and formula
wherein R is Cl -C3 alkyl or allyl, and Rl is CH2 X wherein X is CN, CONH2, SCH3, SO2 CH3 and OCH3.
EP01928355A 2000-04-21 2001-04-17 Treatment of fibromyalgia and chronic fatigue syndrome Withdrawn EP1280530A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19896000P 2000-04-21 2000-04-21
US198960P 2000-04-21
PCT/US2001/010806 WO2001087308A1 (en) 2000-04-21 2001-04-17 Treatment of fibromyalgia and chronic fatigue syndrome

Publications (1)

Publication Number Publication Date
EP1280530A1 true EP1280530A1 (en) 2003-02-05

Family

ID=22735613

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01928355A Withdrawn EP1280530A1 (en) 2000-04-21 2001-04-17 Treatment of fibromyalgia and chronic fatigue syndrome

Country Status (12)

Country Link
EP (1) EP1280530A1 (en)
JP (1) JP2004502651A (en)
KR (1) KR20020089510A (en)
CN (1) CN1418099A (en)
AU (2) AU2001255223B2 (en)
BR (1) BR0110188A (en)
CA (1) CA2404704A1 (en)
HK (1) HK1054190A1 (en)
MX (1) MXPA02010410A (en)
NZ (1) NZ522115A (en)
WO (1) WO2001087308A1 (en)
ZA (1) ZA200208272B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (en) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
CN114980896A (en) * 2019-08-07 2022-08-30 阿克里普斯一有限公司 Pharmaceutical composition of (6AS) -6-methyl-5, 6,6A, 7-tetrahydro-4H-dibenzo [ de, g ] quinoline-10, 11-diol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081343A2 (en) * 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
WO2002005797A2 (en) * 2000-07-17 2002-01-24 Holman Andrew J Use of dopamine d2/d3 receptor agonists to treat fibromyalgia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073555A (en) * 1988-04-04 1991-12-17 George D. McAdory Medicaments intended for combined use in the improvement of lymphocyte function to lower cholesterol levels
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IT1304904B1 (en) * 1998-09-11 2001-04-05 Eisai Co Ltd ANTICOLINESTERASIC DERIVATIVES FOR THE TREATMENT OF FUNCTIONAL AND / OR ORGANIC SYNDROME
DE60022692T2 (en) * 1999-07-01 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo (S, S) reboxetine for the treatment of migraine headache
DE19938823A1 (en) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081343A2 (en) * 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
WO2002005797A2 (en) * 2000-07-17 2002-01-24 Holman Andrew J Use of dopamine d2/d3 receptor agonists to treat fibromyalgia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0187308A1 *

Also Published As

Publication number Publication date
WO2001087308A1 (en) 2001-11-22
JP2004502651A (en) 2004-01-29
NZ522115A (en) 2004-07-30
HK1054190A1 (en) 2003-11-21
BR0110188A (en) 2003-03-05
CN1418099A (en) 2003-05-14
AU5522301A (en) 2001-11-26
KR20020089510A (en) 2002-11-29
CA2404704A1 (en) 2001-11-22
MXPA02010410A (en) 2003-04-25
ZA200208272B (en) 2004-01-26
WO2001087308B1 (en) 2002-05-16
AU2001255223B2 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
RU2095062C1 (en) Blocking agent of withdrawal syndrome that is a result of drug habituation to over intaking drugs and substances causing habituation, pharmacological composition based on thereof and a method of relief or prevention of withdrawal syndrome
RU2488392C2 (en) Melatonin agonist therapy
US9700548B2 (en) Antihistamines combined with dietary supplements for improved health
US6281207B1 (en) Treatment of movement disorders by administration of mirtazapine
US20060039867A1 (en) Method for treating sleep-related breathing disorders with setiptiline
EP1274430B1 (en) Cabergoline for the treatment of fibromyalgia and chronic fatigue syndrome
JP2002541097A (en) Flupirtine in the treatment of fibromyalgia and related conditions
EA003142B1 (en) Drug, possessing an antidepressant effect, its use and method of treatment
US20030212085A1 (en) Treatment of fibromyalgia and chronic fatigue syndrome
US20140271890A1 (en) Controlled-release pharmaceutical composition
ZA200209272B (en) Aromatic polyurethane polyol.
AU2001255223B2 (en) Treatment of fibromyalgia and chronic fatigue syndrome
AU2001255223A1 (en) Treatment of fibromyalgia and chronic fatigue syndrome
WO2002083141A1 (en) Treatment of fibromyalgia and chronic fatigue syndrome
IE904084A1 (en) Treatment of depression
WO2005032546A1 (en) Hypnotic composition
TW201808285A (en) Composition for treating anxiety disorders and disposal method
CZ355998A3 (en) Pyridyl and pyrimidylpiperazines for treating disorders caused by drug removal
Koshucharova et al. Different beta-blocking effects of carvedilol and bisoprolol in humans
JP4344532B2 (en) Composition for rhinitis
WO2025022362A1 (en) Compositions and methods for treating dyskinesia
JP2004026810A (en) Composition for rhinitis
JP2005104926A (en) Hypnotic agent composition
WO2005032592A1 (en) Hypnotic composition
JPH1192376A (en) Nicotine dependence treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021114

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN COMPANY LLC

17Q First examination report despatched

Effective date: 20050415

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050826